162 related articles for article (PubMed ID: 7895243)
1. Effects of naloxone, an opiate receptor antagonist, on coxsackievirus B3 myocarditis in the mouse.
Kishimoto C; Takada H; Hiraoka Y; Shiraki K
Cardiovasc Res; 1995 Jan; 29(1):80-4. PubMed ID: 7895243
[TBL] [Abstract][Full Text] [Related]
2. Naloxone, an opiate receptor antagonist, ameliorates acute experimental autoimmune myocarditis by reducing cytotoxic activities.
Kishimoto C; Okabe TA; Hattori M; Yuan Z
J Cardiovasc Pharmacol; 2008 Nov; 52(5):445-51. PubMed ID: 19033824
[TBL] [Abstract][Full Text] [Related]
3. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
[TBL] [Abstract][Full Text] [Related]
4. Effects of levosimendan in experimental acute coxsackievirus myocarditis.
Latva-Hirvelä J; Kytö V; Saraste A; Vuorinen T; Levijoki J; Saukko P
Eur J Clin Invest; 2009 Oct; 39(10):876-82. PubMed ID: 19772522
[TBL] [Abstract][Full Text] [Related]
5. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration.
Song X; Liu Z; Wang H; Xin Y; Wang X; Chen J; Shi Y; Zhang C; Hui R
Exp Biol Med (Maywood); 2007 Dec; 232(11):1441-8. PubMed ID: 18040068
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Chinese herbal medicine Xin-kang oral liquid on interferon-induction and its antiviral activity in coxsackievirus B3 infected mice].
Wan SJ; Li JN; Zhao H; Wang LX; Huang XZ; Zhu Y; Chen HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Mar; 19(1):77-9. PubMed ID: 16201482
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotective effect of NO-metoprolol in murine coxsackievirus B3-induced myocarditis.
Glück B; Dahlke K; Zell R; Krumbholz A; Decker M; Lehmann J; Wutzler P
J Med Virol; 2010 Dec; 82(12):2043-52. PubMed ID: 20981792
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells.
Kishimoto C; Takada H; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
Cardiovasc Res; 1993 Feb; 27(2):243-8. PubMed ID: 8386064
[TBL] [Abstract][Full Text] [Related]
9. Effects of polyethylene glycol conjugated superoxide dismutase on coxsackievirus B3 myocarditis in mice.
Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
Cardiovasc Res; 1992 Oct; 26(10):956-61. PubMed ID: 1336713
[TBL] [Abstract][Full Text] [Related]
10. Effect of indomethacin in the late phase of coxsackievirus myocarditis in a murine model.
Rezkalla S; Khatib R; Khatib G; Smith F; Walsh M; Sowers J; Kloner R
J Lab Clin Med; 1988 Jul; 112(1):118-21. PubMed ID: 2839587
[TBL] [Abstract][Full Text] [Related]
11. Role of MIP-2 in coxsackievirus B3 myocarditis.
Kishimoto C; Kawamata H; Sakai S; Shinohara H; Ochiai H
J Mol Cell Cardiol; 2000 Apr; 32(4):631-8. PubMed ID: 10756119
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin treatment prevents congestive heart failure in murine encephalomyocarditis viral myocarditis associated with reduction of inflammatory cytokines.
Kishimoto C; Takada H; Kawamata H; Umatake M; Ochiai H
J Pharmacol Exp Ther; 2001 Nov; 299(2):645-51. PubMed ID: 11602677
[TBL] [Abstract][Full Text] [Related]
13. Successive infection of coxsackievirus B3 and encephalomyocarditis virus: an animal model of chronic myocarditis.
Okada I; Matsumori A; Tomioka N; Kawai C
J Pathol; 1992 Jul; 167(3):341-7. PubMed ID: 1325552
[TBL] [Abstract][Full Text] [Related]
14. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis.
Lim BK; Choi JH; Nam JH; Gil CO; Shin JO; Yun SH; Kim DK; Jeon ES
Cardiovasc Res; 2006 Aug; 71(3):517-26. PubMed ID: 16806133
[TBL] [Abstract][Full Text] [Related]
15. [Effects of immunoglobulin on murine myocarditis caused by influenza A virus: experimental study].
Kishimoto C; Hiraoka Y; Takada H; Kurokawa M; Ochiai H
J Cardiol; 2005 Jun; 45(6):247-55. PubMed ID: 15991608
[TBL] [Abstract][Full Text] [Related]
16. The effects of pre-existing coxsackievirus B4 myocardial disease on the expression of coxsackievirus B3 myocarditis.
Khatib R; Reyes MP; Khatib G; Giraldo A
Can J Cardiol; 1993 Jun; 9(5):444-7. PubMed ID: 8394194
[TBL] [Abstract][Full Text] [Related]
17. Cytokine profiles in heart, spleen, and thymus during the acute stage of experimental coxsackievirus B3-induced chronic myocarditis.
Schmidtke M; Glück B; Merkle I; Hofmann P; Stelzner A; Gemsa D
J Med Virol; 2000 Aug; 61(4):518-26. PubMed ID: 10897072
[TBL] [Abstract][Full Text] [Related]
18. [Experimental study of preventive effect of xin-kang oral liquid on acute viral myocarditis in mice].
Zhao H; Wan S; Xu X
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Jun; 15(2):139-42. PubMed ID: 11436642
[TBL] [Abstract][Full Text] [Related]
19. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D.
Kishimoto C; Crumpacker CS; Abelmann WH
Cardiovasc Res; 1988 Oct; 22(10):732-8. PubMed ID: 2855719
[TBL] [Abstract][Full Text] [Related]
20. Trace element changes in the myocardium during coxsackievirus B3 myocarditis in the mouse.
Funseth E; Lindh U; Wesslén L; Friman G; Ilbäck NG
Biol Trace Elem Res; 2000 Aug; 76(2):149-60. PubMed ID: 11049229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
